Thrombophob

Heparin is a heterogeneous, highly sulfated glycosaminoglycan polysaccharide that functions as a potent anticoagulant through its interaction with antithrombin, markedly accelerating the inhibition of coagulation factors such as thrombin (factor IIa) and factor Xa.[1][2] It is primarily extracted from the mucosal tissues of porcine intestines or, historically, bovine lungs, making its production dependent on animal slaughter byproducts.[3][4] Discovered in 1916 by second-year medical student Jay McLean at Johns Hopkins University while investigating procoagulant lipid extracts from organs, which unexpectedly revealed anticoagulant properties, heparin was subsequently purified and named by his mentor William Henry Howell in 1918.[5][6] Clinically, unfractionated heparin is administered intravenously or subcutaneously for rapid anticoagulation in settings including venous thromboembolism prophylaxis and treatment, acute coronary syndromes, cardiopulmonary bypass during surgery, and hemodialysis to prevent clotting in extracorporeal circuits.[1] Its use has been foundational in antithrombotic therapy since the 1930s, though it carries risks of bleeding, heparin-induced thrombocytopenia, and osteoporosis with prolonged administration.[1] Production challenges, stemming from reliance on animal sources, have prompted regulatory scrutiny over quality control and supply chain integrity, exemplified by the 2008 worldwide crisis where heparin batches contaminated with oversulfated chon